Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

By sjmartinez • October 22, 2022

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. PMID: 34597472.

Tags: BladderCancer, blcsm, Hematology/Oncology, immune checkpoint, immunotherapy, inhibitors, Outcomes, Publications, urinary tract neoplasms, uroonc, urothelial carcinoma, utuc

Related Posts

Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller[...]

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]